FIG. 7.
Results for heterologous (SIVmac239; 100 MID50 intravenously) virus rechallenge (large open arrow) and in vivo depletion of CD8+ cells (doses indicated by small open arrows) in animal Rh 155. Graphing conventions are as for Fig. 3. LNMC from a biopsy specimen obtained after two of three doses of anti-CD8 MAb showed 14% residual CD3+ CD8+ cells, compared to 3% in matched PBMC.